SCHEMBL4764024

SCHEMBL4764024

Nc1ccc(C(=O)N2CCC2)cc1

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HPGD P15428 6/20 0.69
ALDH1A1 P00352 3/20 0.69
CA12 O43570 3/20 0.64
CA1 P00915 3/20 0.64
CA2 P00918 3/20 0.64
CA7 P43166 3/20 0.64
CA9 Q16790 3/20 0.64
CA14 Q9ULX7 3/20 0.64
KMT2A Q03164 4/20 0.62
MEN1 O00255 3/20 0.62
SMN1; SMN2 Q16637 2/20 0.62
LMNA P02545 1/20 0.62
KDM4E B2RXH2 1/20 0.60
HTT P42858 1/20 0.58
MAPK1 P28482 1/20 0.56
MGLL Q99685 1/20 0.55
MLYCD O95822 1/20 0.55
L3MBTL3 Q96JM7 1/20 0.55
TSHR P16473 1/20 0.53
POLB P06746 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL264516 0.96 HPGD (0.76) HPGDALDH1A1CA12CA1CA2
SCHEMBL12156421 0.94 HPGD (0.80) HPGDALDH1A1CA12CA1CA2
Hydrochloric Acid SCHEMBL3562269 0.94 HPGD (0.73) HPGDALDH1A1CA12CA1CA2
SCHEMBL1590985 0.94 HPGD (0.80) HPGDALDH1A1CA12CA1CA2
SCHEMBL20261717 0.91 CA12 (0.73) HPGDALDH1A1CA12CA1CA2
SCHEMBL4037766 0.88 KMT2A (0.72) HPGDALDH1A1CA12CA1CA2
SCHEMBL24161311 0.86 HPGD (0.61) HPGDALDH1A1CA12CA1CA2
SCHEMBL4689643 0.86 HPGD (0.61) HPGDALDH1A1CA12CA1CA2
SCHEMBL14466291 0.84 SIGMAR1 (0.60) HPGDALDH1A1CA12CA1CA2
SCHEMBL12460085 0.84 HPGD (0.55) HPGDALDH1A1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4019518-A1 TYK2 INHIBITORS AND USES THEREOF Nimbus Lakshmi, Inc. (US) 2022-06-29 EP disclosed
EP-4019518-A1 TYK2 INHIBITORS AND USES THEREOF Nimbus Lakshmi, Inc. (US) 2022-06-29 EP disclosed
EP-3110820-B1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI INC (US) 2022-04-06 EP disclosed
EP-3110820-B1 TYK2 INHIBITORS AND USES THEREOF NIMBUS LAKSHMI INC (US) 2022-04-06 EP disclosed
EP-3189048-B1 AMINOINDANE-, AMINOTETRAHYDRONAPHTHALENE- AND AMINOBENZOCYCLOBUTANE-DERIVED PRMT5-INHIBITORS CTXT PTY LTD (AU) 2021-03-17 EP disclosed
WO-2020224568-A1 CDK INHIBITORS QILU REGOR THERAPEUTICS INC. (CN) 2020-11-12 WO disclosed
US-10752624-B2 Kinase inhibitors ORIGENIS GMBH (DE) 2020-08-25 US disclosed
US-10196390-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2019-02-05 US disclosed
US-10196390-B2 TYK2 inhibitors and uses thereof NIMBUS LAKSHMI, INC. (US) 2019-02-05 US disclosed
US-20180305356-A1 NOVEL KINASE INHIBITORS ORIGENIS GMBH (DE) 2018-10-25 US disclosed
EP-1948658-A1 PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS GLAXO GROUP LIMITED (GB) 2008-07-30 EP disclosed
EP-1948659-A1 PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS GLAXO GROUP LIMITED (GB) 2008-07-30 EP disclosed
US-20080004295-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-01-03 US disclosed
US-20080004295-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-01-03 US disclosed
US-20080004295-A1 NOVEL COMPOUNDS GLAXO GROUP LIMITED (GB) 2008-01-03 US disclosed
WO-2007042298-A1 PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS GLAXO GROUP LIMITED (GB) 2007-04-19 WO disclosed
WO-2007042298-A1 PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS GLAXO GROUP LIMITED (GB) 2007-04-19 WO disclosed
WO-2007042299-A1 PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS GLAXO GROUP LIMITED (GB) 2007-04-19 WO disclosed
WO-2007042299-A1 PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS GLAXO GROUP LIMITED (GB) 2007-04-19 WO disclosed
WO-2007040440-A1 NEW PYRIMIDINE DERIVATIVES AND THEIR USE IN THERAPY AS WELL AS THE USE OF PYRIMIDINE DERIVATIVES IN THE MANUFACTURE OF A MEDICAMENT FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER’S DISEASE ASTRAZENECA AB (SE) 2007-04-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10196390-B2 TYK2 inhibitors and uses thereof TYK2, JAK2, JAK1 HPGD 4476/4885ALDH1A1 4827/4885CA12 4833/4885
US-20180305356-A1 NOVEL KINASE INHIBITORS LRRK2, MYLK2, MYLK HPGD 4082/4885ALDH1A1 4333/4885CA12 4858/4885
US-20080004295-A1 NOVEL COMPOUNDS SYK, BTK, LCK HPGD 2135/4885ALDH1A1 2075/4885CA12 4748/4885
US-10752624-B2 Kinase inhibitors LRRK2, MYLK2, MYLK HPGD 4156/4885ALDH1A1 4184/4885CA12 4853/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.